ATAI
demonstrated safety level and plasma concentrations of in line with previous trials potential therapeutic plasma levels no serious adverse events reported asymptomatic prolongation phase study trial design results summary | ATAI
Company
Deck Type
Sector
Industry
Deck date
January 2024
Slide
23 of 34
Similar slides by ATAI
See diffirences between slides (animation)
Investor Presentation
October 2023
demonstrated safety level and plasma concentrations of in line with previous trials phase study trial design results summary | ATAI
Related slides by other companies
BioAtla
Investor Presentation
November 2022
phase study design with | BioAtla
BioAtla
Investor Presentation
November 2022
phase study design with in refractory patients | BioAtla
Checkmate Pharmaceuticals
IPO
August 2020
phase study design | Checkmate Pharmaceuticals
BioAtla
Investor Presentation
January 2024
cab phase potentially registrational ups study design | BioAtla
Other recent decks by ATAI
See all presentations (13 decks)
Investor Presentation
October 2023
Investor Conference
May 2023
Investor Presentation
April 2023
Investor Presentation
March 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights